ESMO 2024 Summary: eBC Panel Discussion on Key Studies - KEYNOTE-522, I-SPY 2.2, and NATALEE | VuMedi

This video is featured in the 2024 ESMO Annual Meeting Insights Hub

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: eBC Panel Discussion on Key Studies - KEYNOTE-522, I-SPY 2.2, and NATALEE

By 2024 ESMO Annual Meeting Insights Hub FEATURING Sara Tolaney, Hope Rugo

By 2024 ESMO Annual Meeting Insights Hub FEATURING Sara Tolaney, Hope Rugo

514 views

October 4, 2024

ESMO 2024 Highlights & Early Stage Discussion

00:00

KEYNOTE-522: Pembrolizumab in Triple Negative BC

00:47

I-SPY 2.2: Tailoring Neoadjuvant Treatment

10:13

Ribociclib Insights: NATALEE Updates, Eligibility, Age-Based Outcomes, Adjuvant treatment selection

21:55

Comments 0

Login to view comments. Click here to Login